Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series

This study investigates the effect of semaglutide, a GLP-1 agonist, on weight and glycemic control in overweight or obese individuals with spinal cord injury (SCI). Semaglutide is administered once a week for 26 weeks. The study found that semaglutide administration led to decreases in body weight, fat tissue mass, and visceral adipose tissue volume in the treatment group, as well as improved fasting plasma glucose and HbA1c levels. These favorable changes suggest a reduced risk for the development of cardiometabolic disease in obese individuals with SCI.

• 1
  After 26 weeks of semaglutide administration, total body weight, fat tissue mass, total body fat percent, and visceral adipose tissue volume decreased.
• 2
  Fasting plasma glucose and HbA1c values decreased after 26 weeks of semaglutide administration.
• 3
  In the control group, total body weight, fat tissue mass, total body fat percent, and visceral adipose tissue volume increased after 26 weeks.